Meta AnalysisID 2931
甲亢放射性碘治疗后二次治疗风险：一项Meta分析
CRD42022356973
What is the prevalence of second treatment in patients with radioiodine therapy ?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2931
- Evidence Id
- 11489
- Core Evidence Id
- 11489
- Source Meta Analysis Id
- 2875
- Herb2 Meta Analysis Id
- HBMA002875
- Crd Id
- CRD42022356973
- Title
- Second Treatment Risk After Radioiodine Therapy for Hyperthyroidism: A Meta-Analysis
- Review Question
- What is the prevalence of second treatment in patients with radioiodine therapy ?
- Study Type Included
- randomized controlled trial and Clinical trial will be included.
- Condition Being Studied
- Hyperthyroidism is a common disease of the endocrine system, which is caused by excessive thyroid hormone synthesis or secretion by the thyroid gland. Laboratory tests show that thyroid hormones T3 and T4 are increased, and TSH is decreased. Patients with hyperthyroidism often have systemic dysfunction and disorders. The main manifestations are systemic hypermetabolic symptoms such as palpitations, shaking hands, fear of heat, weight loss, hyperactivity, eating more, drinking more and so on. The global incidence of hyperthyroidism ranges from 0.2% to 1.3%. At present, there are three main methods for the treatment of hyperthyroidism: drug therapy, radioiodine therapy and surgical treatment. Treatment rates with reflex iodine are higher in North America, and rates with internal medicine are higher in Europe, Asia, and Oceania. How to accurately manage the outcome of radioiodine therapy in patients with hyperthyroidism and develop individualized drug methods are clinical problems that endocrinologists and nuclear medicine doctors are actively solving at present. Therefore, it is particularly important to evaluate the condition of patients with radioiodine therapy before treatment, and the prognosis and recurrence risk after treatment.
- Participant
- The inclusion criteria of clinical cases were as follows: ① over 18 years old; ② primary hyperthyroidism; ③ Patients with hyperthyroidism treated with iodine-131 for the first time; ④ No ATD drugs were used after treatment; Exclusion criteria for clinical cases: ① complicated with other organ and system-related diseases. ② Treatment other than drug therapy before and after iodine therapy;
- Animal
- Human Disease Modelled
- Intervention
- hyperthyroidism treated with iodine-131
- Comparator Control
- patient after the treatment with iodine-131 become hypothyroidism.
- Main Outcome
- Objective response rate (ORR)
- Outcome Measure
- Additional Outcome
- Disease control rate，DCR
- Study Method
- Meta-analysis, Prospective meta-analysis (PMA), Review of reviews, Systematic review
- Keyword
- Graves Disease; Humans; Hyperthyroidism; Iodine Radioisotopes
- Contact
- yihang li [email protected]
- Organisational Affiliation
- Kunming medical university https://www.kmmu.edu.cn/list3.aspx
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-08-31
- Registration Date
- 2022-09-11
- Anticipated Start Date
- 2022-09-01
- Anticipated Completion Date
- 2022-10-31
- Title Cn
- 甲亢放射性碘治疗后二次治疗风险：一项Meta分析
- Title En
- Second Treatment Risk After Radioiodine Therapy for Hyperthyroidism: A Meta-Analysis
- Bilingual Status
- complete